Form 4: GoodRx Director Rey-Giraud Acquires Deferred Stock Units

Agnes Rey-Giraud, a director of GoodRx Holdings, Inc., acquired 28,398 deferred stock units on June 6, 2024, according to a recent SEC filing.

Summary

• On June 6, 2024, Agnes Rey-Giraud, a director of GoodRx Holdings, Inc., acquired 28,398 deferred stock units.
• These deferred stock units represent a contingent right to receive one share of Class A common stock each.
• The units vest in full on the earlier of (i) the one-year anniversary of June 6, 2024, or (ii) the date of the 2025 Annual Meeting of Stockholders, contingent upon continued service.
• The deferred stock units will settle on the earliest of December 31, 2027, separation from service, a change in control, death, or disability.
• Following the transaction, Rey-Giraud beneficially owns 101,153 shares of Class A Common Stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of a director's stock acquisition, which is neither overtly positive nor negative.

Positives

• The acquisition of deferred stock units by a director signals confidence in the company's future.

Future Outlook

The deferred stock units vest based on continued service and will settle upon specific future events, indicating a long-term commitment from the director.

Industry Context

Director stock acquisitions are common in the pharmaceutical and healthcare technology industries, often used to align management interests with shareholder value.

Comparison to Industry Standards

• Director compensation packages often include deferred stock units to incentivize long-term performance, similar to practices at companies like Teladoc Health and CVS Health.
• The vesting schedule and settlement terms are typical for director equity grants in publicly traded companies.

Stakeholder Impact

• The acquisition of deferred stock units by a director can positively influence shareholder confidence.

Key Dates